Study on 16 years hepatitis B vaccine of Jiachen bio, a subsidiary of Chongqing beer

According to the announcement, in view of the fact that the development of new drugs has the characteristics of high risk, high investment, strong professionalism and long cycle, as well as consultation with relevant parties, the company decided to agree to the board of directors of Chongqing Jiachen Bioengineering Co., Ltd (hereinafter referred to as Jiachen company), a holding subsidiary, not to apply for phase III clinical trials of the combined drug group, and not to start new combined drugs Group II clinical study decision Chongqing Beer's announcement announced the end of the story of 16 years In October 1998, Chongqing beer, which had been on the market for one year, announced to acquire 52% of the equity of Jiachen biology held by Chongqing beer (Group) Co., Ltd., and said that Jiachen biology was fully engaged in the development of new drugs for the treatment of hepatitis B and other major projects In the past 16 years, the news about vaccine of Chongqing beer has been coming out constantly In 2010, Chongqing beer announced the progress of vaccine research every month Under the stimulation of this news, the stock price of Chongqing beer has been rising continuously On December 7, 2011, Chongqing beer released a notice on the Unblinding of the second phase clinical data of hepatitis B vaccine According to the data, the therapeutic effect of hepatitis B vaccine developed by Chongqing beer for 13 years is far lower than the market expectation After the resumption of trading, Chongqing beer fell nine words in a row, from 83.12 yuan all the way down to about 20 yuan, resulting in heavy losses for investors holding its shares On August 13, 1998, Chongqing beer (Group) Co., Ltd (Chongqing heavy beer group), the Third Military Medical University of the people's Liberation Army (the Third Military University) and Chongqing University respectively contributed 14 million yuan, 3 million yuan and 3 million yuan to establish Chongqing Jiachen Bioengineering Co., Ltd.